Bagneux, France – (BUSINESS WIRE) – Regulatory News:
Genome vision (FR0011799907 – GV, PEA-PME target)Biotechnology companies developing tools and services dedicated to the analysis and control of genomic modifications today announce the availability of preparatory documents for the Annual General Meeting of Shareholders on June 28, 2022 at 2:00 pm. did. des Meuniers, 92220 Bagneux
In the current state of health, we will prioritize shareholders to vote remotely or by proxy in accordance with the procedures detailed in the notice of our meeting issued at BALO on May 23, 2022. Is recommended.
For shareholders wishing to attend a general meeting of shareholders, please remember that the welcome of shareholders is subject to barrier gestures, especially wearing a mask during the general meeting of shareholders.
Preparatory documents are available upon request from us or can be viewed under the Investors / General Assembly on our website.
Uncertainty due to the current circumstances associated with the Covid-19 epidemic may change the procedure for holding, attending, and voting for the General Assembly in accordance with applicable legal and regulatory provisions. Therefore, shareholders should consult with the section dedicated to the general meeting of shareholders on a regular basis.
About Genome Vision
GENOMIC VISION is a biotechnology company that develops products and services that specialize in the analysis of genomic modifications (structural and functional) and the quality and safety of these modifications, especially in genomic editing and bioproduction processes. is. .. Based on DNA combing technology and artificial intelligence, GENOMICVISION’s unique tools provide the robust quantitative measurements needed for reliable characterization of DNA changes in the genome. These tools are used for early detection of cancer and diagnosis of genetic disorders, especially to monitor DNA replication in cancer cells. Based in Bagneux, Paris, the company has approximately 30 employees. GENOMIC VISION is listed on Compartment C (Euronext: GV – ISIN: FR0011799907), the regulated market for Euronext in Paris.
Index member CAC® Small and medium When CAC® All can be traded
This press release contains implicit or explicit forward-looking statements related to Genomic Vision and its activities. Genomic Vision believes that these forward-looking statements are based on reasonable assumptions. However, the forecasts set forth in these forward-looking statements affected by risk, including those listed in the Risk Factors section of the Universal Registration Document submitted to the Autorité des Financial Markets (Autorité des Financial Markets). We cannot guarantee achievement. AMF) Available on the company’s website (www.genomicvision.com) on April 14, 2022, it responds to changes in economic conditions, financial markets, and markets in which GenomicVision resides. The forward-looking statements contained in this press release are also exposed to risks unknown to Genomic Vision or risks that Genomic Vision does not consider materiality at this time. Realizing all or part of these risks will result in the actual results, financial position, performance or outcomes of Genomic Vision differing significantly from the results, financial position, performance or performance shown in these forward-looking statements. There is a possibility.
This press release and the information contained therein do not constitute an offer or invitation to sell or subscribe to Genomic Vision shares, or an order or invitation to purchase or subscribe to Genomic Vision shares, and shall be construed in any country. It’s not a thing either. Distribution of this press release in certain countries may violate the legal provisions in force. Therefore, anyone in possession of a press release must notify themselves of regional restrictions and comply with them.
Chairman of the Management Committee
like that. : +33 1 49 08 07 51
like that. : +33 1 42 68 29 70
Investor public relations
& Strategic communication
like that. : +33 1 44 71 94 94